Skip to main content
Erschienen in: Clinical Autonomic Research 6/2022

08.10.2022 | Research Article

Is 18F-DOPA a valid cardiac sympathetic neuroimaging agent?

verfasst von: David S. Goldstein, Courtney Holmes

Erschienen in: Clinical Autonomic Research | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18F-Dopamine positron emission tomography is a validated method for identifying cardiac noradrenergic deficiency, a characteristic feature of Lewy body forms of neurogenic orthostatic hypotension; however, 18F-dopamine is a research drug. Brain 18F-DOPA positron emission tomography is FDA-approved. Since 18F-DOPA is converted to 18F-dopamine in the heart, 18F-DOPA might be useful for cardiac sympathetic neuroimaging. We compared 18F-DOPA with 18F-dopamine in patients who either had or did not have low 18F-dopamine-derived radioactivity.

Methods

Brain and cardiac 18F-DOPA scanning and cardiac 18F-dopamine scanning were done on separate days in patient groups with neurogenic orthostatic hypotension or Parkinsonism or control subjects across a range of values for 18F-dopamine-derived radioactivity. The lower limit of normal for myocardial 18F-dopamine-derived radioactivity was 6000 Bq-kg/cc-MBq. We also examined inter-relationships among cardiac 18F-DOPA-derived radioactivity, cardiac 18F-dopamine-derived radioactivity, putamen/occipital cortex ratios of 18F-DOPA-derived radioactivity, and Unified Parkinson Disease Rating Scale scores in patients with or without Parkinsonism. For putamen/occipital cortex ratios, the cutoff value was 2.70.

Results

Twelve subjects had severely decreased and eight normal cardiac 18F-dopamine-derived radioactivity. Cardiac 18F-DOPA-derived radioactivity did not distinguish the two groups and was unrelated to 18F-dopamine-derived radioactivity. Left ventricular myocardial 18F-DOPA-derived radioactivity was poorly resolved from that in the chamber. Putamen/occipital cortex ratios of 18F-DOPA-derived radioactivity were negatively correlated with Unified Parkinson Disease Rating Scale scores (− 0.67, p = 0.0015).

Conclusions

18F-DOPA does not seem to be a valid cardiac sympathetic neuroimaging agent, although brain 18F-DOPA scanning provides a biomarker of Parkinsonism.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, Holden JE (1998) Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med 39:1884–1891PubMed Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, Holden JE (1998) Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med 39:1884–1891PubMed
2.
Zurück zum Zitat Chroustova D, Trnka J, Pudlac A, Obermannova B, Lambert L (2020) The role of (18)F-DOPA PET/CT in the diagnosis of the congenital focal form of hyperinsulinism in children. Rev Esp Med Nucl Imagen Mol (Engl Ed) 39:279–283PubMed Chroustova D, Trnka J, Pudlac A, Obermannova B, Lambert L (2020) The role of (18)F-DOPA PET/CT in the diagnosis of the congenital focal form of hyperinsulinism in children. Rev Esp Med Nucl Imagen Mol (Engl Ed) 39:279–283PubMed
3.
Zurück zum Zitat Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667–1676CrossRefPubMed Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667–1676CrossRefPubMed
4.
Zurück zum Zitat Eldrup E, Richter AE, Christensen NJ (1989) Dopa, norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle dopa. Am J Physiol 256:E284–E287PubMed Eldrup E, Richter AE, Christensen NJ (1989) Dopa, norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle dopa. Am J Physiol 256:E284–E287PubMed
5.
Zurück zum Zitat Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72CrossRefPubMed Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72CrossRefPubMed
6.
Zurück zum Zitat Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676CrossRefPubMed Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676CrossRefPubMed
7.
Zurück zum Zitat Goldstein DS, Eisenhofer G, Dunn BB, Armando I, Lenders J, Grossman E, Holmes C, Kirk KL, Bacharach S, Adams R et al (1993) Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22:1961–1971CrossRefPubMed Goldstein DS, Eisenhofer G, Dunn BB, Armando I, Lenders J, Grossman E, Holmes C, Kirk KL, Bacharach S, Adams R et al (1993) Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22:1961–1971CrossRefPubMed
8.
Zurück zum Zitat Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R, Conant S, Eldadah BA (2008) Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14:600–607CrossRefPubMedPubMedCentral Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R, Conant S, Eldadah BA (2008) Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14:600–607CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y (2018) Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord 52:90–93CrossRefPubMed Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y (2018) Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord 52:90–93CrossRefPubMed
10.
Zurück zum Zitat Goldstein DS, Sewell L, Sharabi Y (2011) Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 310:118–122CrossRefPubMed Goldstein DS, Sewell L, Sharabi Y (2011) Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 310:118–122CrossRefPubMed
11.
Zurück zum Zitat Goldstein DS, Sharabi Y (2019) The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res 1702:74–84CrossRefPubMed Goldstein DS, Sharabi Y (2019) The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res 1702:74–84CrossRefPubMed
12.
Zurück zum Zitat Goldstein DS, Tack C (2000) Non-invasive detection of sympathetic neurocirculatory failure. Clin Auton Res 10:285–291CrossRefPubMed Goldstein DS, Tack C (2000) Non-invasive detection of sympathetic neurocirculatory failure. Clin Auton Res 10:285–291CrossRefPubMed
13.
Zurück zum Zitat Goyal H, Sharma A, Patel C, Deepak KK, Tripathi M, Gupta P, Kumar R, Bal CS, Goyal V (2022) Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET/CT in patients with autonomic dysfunction: feasibility study in IPD patients. J Nucl Cardiol 29:1280–1290CrossRefPubMed Goyal H, Sharma A, Patel C, Deepak KK, Tripathi M, Gupta P, Kumar R, Bal CS, Goyal V (2022) Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET/CT in patients with autonomic dysfunction: feasibility study in IPD patients. J Nucl Cardiol 29:1280–1290CrossRefPubMed
14.
Zurück zum Zitat Helali M, Addeo P, Heimburger C, Detour J, Goichot B, Bachellier P, Namer IJ, Taieb D, Imperiale A (2016) Carbidopa-assisted (18)F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. Ann Nucl Med 30:659–668CrossRefPubMed Helali M, Addeo P, Heimburger C, Detour J, Goichot B, Bachellier P, Namer IJ, Taieb D, Imperiale A (2016) Carbidopa-assisted (18)F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. Ann Nucl Med 30:659–668CrossRefPubMed
15.
Zurück zum Zitat Hoshi H, Kuwabara H, Leger G, Cumming P, Guttman M, Gjedde A (1993) 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57–69CrossRefPubMed Hoshi H, Kuwabara H, Leger G, Cumming P, Guttman M, Gjedde A (1993) 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57–69CrossRefPubMed
16.
Zurück zum Zitat Jokinen P, Helenius H, Rauhala E, Bruck A, Eskola O, Rinne JO (2009) Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 50:893–899CrossRefPubMed Jokinen P, Helenius H, Rauhala E, Bruck A, Eskola O, Rinne JO (2009) Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 50:893–899CrossRefPubMed
17.
Zurück zum Zitat Kulen J, Linevitz A, Lerman H, Freedman N, Kestenbaum M, Shiner T, Giladi N, Even-Sapir E (2020) [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson’s disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: proof-of-concept study. J Integr Neurosci 19:489–494CrossRef Kulen J, Linevitz A, Lerman H, Freedman N, Kestenbaum M, Shiner T, Giladi N, Even-Sapir E (2020) [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson’s disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: proof-of-concept study. J Integr Neurosci 19:489–494CrossRef
18.
Zurück zum Zitat Lamotte G, Holmes C, Sullivan P, Lenka A, Goldstein DS (2020) Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Ann Clin Transl Neurol 7:2450–2460CrossRefPubMedPubMedCentral Lamotte G, Holmes C, Sullivan P, Lenka A, Goldstein DS (2020) Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Ann Clin Transl Neurol 7:2450–2460CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lamotte G, Holmes C, Wu T, Goldstein DS (2019) Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord 67:27–33CrossRefPubMedPubMedCentral Lamotte G, Holmes C, Wu T, Goldstein DS (2019) Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord 67:27–33CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat van Beek AP, de Heide LJ, van Ginkel B, Slart RH, van der Horst-Schrivers AN, Boellaard R, de Vries EG, Noordzij W, Glaudemans AW (2017) Pancreatic uptake by 18F-FDOPA PET/CT in patients with hypoglycemia after gastric bypass surgery compared with controls with or without carbidopa pretreatment. Clin Nucl Med 42:163–168CrossRefPubMed van Beek AP, de Heide LJ, van Ginkel B, Slart RH, van der Horst-Schrivers AN, Boellaard R, de Vries EG, Noordzij W, Glaudemans AW (2017) Pancreatic uptake by 18F-FDOPA PET/CT in patients with hypoglycemia after gastric bypass surgery compared with controls with or without carbidopa pretreatment. Clin Nucl Med 42:163–168CrossRefPubMed
Metadaten
Titel
Is 18F-DOPA a valid cardiac sympathetic neuroimaging agent?
verfasst von
David S. Goldstein
Courtney Holmes
Publikationsdatum
08.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 6/2022
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-022-00885-y

Weitere Artikel der Ausgabe 6/2022

Clinical Autonomic Research 6/2022 Zur Ausgabe